Apyx Medical Corporation (NASDAQ:APYX) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Apyx Medical Corporation (NASDAQ:APYX) have received a consensus rating of “Moderate Buy” from the five research firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $6.6667.

A number of equities analysts have recently commented on the company. Zacks Research raised Apyx Medical to a “hold” rating in a research report on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apyx Medical in a research report on Monday, December 29th. Wall Street Zen upgraded shares of Apyx Medical to a “hold” rating in a research note on Saturday, November 22nd. Roth Mkm started coverage on Apyx Medical in a report on Monday, December 15th. They issued a “buy” rating and a $6.00 target price on the stock. Finally, BTIG Research upgraded Apyx Medical from a “neutral” rating to a “buy” rating and set a $6.00 price target on the stock in a research note on Wednesday.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of APYX. Perkins Capital Management Inc. increased its stake in Apyx Medical by 4.9% in the fourth quarter. Perkins Capital Management Inc. now owns 85,000 shares of the company’s stock valued at $298,000 after purchasing an additional 4,000 shares during the period. State Street Corp raised its stake in Apyx Medical by 6.8% during the 4th quarter. State Street Corp now owns 116,706 shares of the company’s stock valued at $408,000 after acquiring an additional 7,400 shares during the last quarter. Geode Capital Management LLC lifted its position in Apyx Medical by 2.1% during the 4th quarter. Geode Capital Management LLC now owns 358,829 shares of the company’s stock worth $1,257,000 after acquiring an additional 7,551 shares during the period. Citadel Advisors LLC purchased a new position in shares of Apyx Medical in the 3rd quarter valued at approximately $28,000. Finally, Fisher Asset Management LLC acquired a new position in shares of Apyx Medical in the second quarter valued at approximately $34,000. Institutional investors and hedge funds own 55.33% of the company’s stock.

Key Stories Impacting Apyx Medical

Here are the key news stories impacting Apyx Medical this week:

• Positive Sentiment: Q4 results: Apyx reported EPS of ($0.03) vs. consensus ($0.06) and revenue of $19.16M (vs. $19.12M expected) — the beat supports near‑term sentiment and shows improving top‑line execution. Apyx Medical Corp (APYX) Q4 2025 Earnings Call Highlights
• Positive Sentiment: FY‑2026 revenue guidance raised: management guided revenue to $57.5M–$58.5M, above the consensus ~$55.9M — this upward guidance is the main constructive catalyst for the stock today. Apyx Medical Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Growth driver: the company reiterated a 9%–11% revenue growth target for 2026 and cited acceleration of the AYON Body Contouring System launch — investors may view product momentum as evidence that guidance is achievable. Apyx Medical outlines 9%–11% revenue growth target for 2026 as AYON launch
• Neutral Sentiment: Analyst/press coverage: earnings breakdowns and summaries (Benzinga, MarketBeat coverage and the company’s press release/conference call transcript) are available for investors to review management commentary and model impacts. Earnings Breakdown: Apyx Medical Q4 Company Press Release / Call Transcript
• Negative Sentiment: Profitability remains a concern: Apyx reported a negative net margin (~‑30%) and very negative ROE (~‑151%), indicating continued losses and execution risks despite revenue growth. Apyx Medical Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
• Negative Sentiment: Short interest moved higher in late February (173,573 shares, +22.3% vs. prior period; ~0.5% of float, ~2.7 days to cover). Elevated shorting can add volatility and represents a potential headwind if negative sentiment persists. (Data point reported in filings/market feeds.)
• Neutral Sentiment: Data anomalies on short interest in early March (entries showing 0 shares) appear inconsistent — treat those figures as unreliable until exchanges/custodians reconcile the reports.

Apyx Medical Stock Performance

Shares of APYX stock opened at $3.45 on Wednesday. Apyx Medical has a 52 week low of $0.76 and a 52 week high of $4.50. The firm has a 50 day moving average of $3.74 and a two-hundred day moving average of $3.31. The company has a quick ratio of 3.61, a current ratio of 4.44 and a debt-to-equity ratio of 5.69. The stock has a market capitalization of $131.93 million, a PE ratio of -9.58 and a beta of 1.61.

Apyx Medical (NASDAQ:APYX) last released its earnings results on Tuesday, March 10th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.03. Apyx Medical had a negative return on equity of 151.01% and a negative net margin of 30.35%.The firm had revenue of $19.16 million during the quarter, compared to analysts’ expectations of $19.12 million. On average, research analysts predict that Apyx Medical will post -0.68 EPS for the current fiscal year.

About Apyx Medical

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.